GlobeNewsWire
02 Mar 2026, 21:01 UTC · 35w ago
Impact · against what's priced in
BDTX shares are likely to see positive movement following the report of positive Phase 2 results for silevertinib, specifically the absence of de novo brain metastases in frontline non-classical EGFRm NSCLC patients. The announcement of upcoming investor conferences is routine and not a catalyst.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish
Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in frontline patients with non-classical EGFRm NSCLC, including a lack of de novo brain metastases.
More positive than 99% of claims this week
Black Diamond Therapeutics will participate in upcoming investor conferences, including the Raymond James BioPharma Conference on April 14, 2026.
Continue reading
5 related stories
The report of positive Phase 2 results for silevertinib, including a lack of de novo brain metastases in frontline non-classical EGFRm NSCLC patients, provides a material positive catalyst for the company's lead oncology candidate.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 38% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The company reported positive Phase 2 results for silevertinib with no patients developing de novo brain metastases.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
10h ago
−21.8%
Price is moving against the score
$1.90 vs $2.43 close before publication (Mar 2) · not market-adjusted
BDTX chart →
